International Stem Cell Corporation (OTCBB:ISCO),
www.intlstemcell.com,
a California-based biotechnology company focused on therapeutic and
research products, congratulates Advanced Cell Technology, Inc. (ACT) on
the issuance of its recent patent, U.S. Patent Number 7,736,896,
covering a method for producing retinal pigment epithelial cells.
As licensee of the retinal cell technology covered by this ACT patent,
ISCO looks forward to building on this discovery, either independently
or in collaboration with ACT, with the goal of advancing the search for
treatment of such diseases as Macular Degeneration and Retinitis
Pigmentosa, leading causes of blindness in adults, both in the US and
the World.
In addition to its licensed interest in the ACT patent, ISCO is
developing its own proprietary technology for creating and implanting
retinal pigment epithelial (RPE) cells that may be usable either in
conjunction with its licensed technology from ACT or independently.
'This is just one more example of the remarkable advancement in science
toward the treatment of life's more dreaded diseases, and we are proud
to be one of the leading pioneers in that effort,' said Kenneth Aldrich,
Chairman of ISCO.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells (hpSCs) from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing sexes, ages and racial groups. This offers the potential to
create the first true stem cell bank, UniStemCell(TM), while
avoiding the ethical issue of using fertilized eggs. ISCO also produces
and markets specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology. More
information is available at ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS Statements pertaining to anticipated technological developments and
therapeutic applications, and other opportunities for the company and
its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Brian
Lundstrom, President 760-640-6383 bl@intlstemcell.com |